ESTRO 36 Abstract Book

753 / 1082

S737 ESTRO 36 2017
_______________________________________________________________________________________________
irradiated vertebrae (43.9% of esophagitis if more than 5
vertebrae are irradiated versus 25.3% if less than 6
vertebrae are irradiated).
Conclusion
The incidence of esophagitis after palliative CRT of
cervico-thoracic spinal metastases led to considering
static or dynamic Intensity Modulated Radiation Therapy
(IMRT) to reduce the dose to organ at risk (esophagus).
IMRT could be primarily beneficial if palliative
radiotherapy concerns vertebrae between C5 and T4 and
if it affects more than 5 vertebrae.
EP-1392 Prognostic factors for survival in patients with
bone metastases
P.M. Samper Ots1, M. Hernandez Miguel1, E. Amaya
Escobar1, M.D. De las Peñas Cabrera1
1 Hospital Rey Juan Carlos, Servicio de Oncologia
Radioterapica, Mostoles - Madrid, Spain
Purpose or Objective
To analyze the prognostic factors for survival in patients
with bone metastases.
Material and Methods
Retrospective analysis of 104 patients referred for
treatment of bone metastases, median age was 59 years,
69 males (66.3%). The most common primary tumors were:
lung 36 cases (34.6%), prostate 24 (23.1%) and breast 13
(12.6%). The means time diagnosis of bone metastases was
14.55 ± 2 months. 85 patients were treated with 3DRT
(81.7%), 9 SBRT (8.7%) and 10 no treatment (9.6%). The
study was approved by the Ethics Committee for Clinical
Research (CEIC) and meets the standards of data
protection. For statistical analysis SPSS version 22.0 was
used.
Results
70 patients (67.3%) died with a median survival of 14.4
months after the diagnosis of bone metastases. Survival
according to the treatment was: 3DRT 13.73 ± 21.3
months, SBRT 20.7 ± 12.0 months and without RT 10.48 ±
10.7 months (p <0.001). The median survival after end of
radiotherapy was 19.4 ± 5.66 months. Prognostic factors
for survival were: primary tumor controlled versus
uncontrolled 45.3 ± 15.4 versus 7.64 ± 1.09 months (p =
0.001), metastases in other organs 15.23 ± 5.2 versus not
22 ± 4.7 months (p = 0.04), lymph node metastasis 13 ±
5.06 versus not 18 ± 4.3 months (p = 0.007), liver
metastases 6.42 ± 1.52 versus not 24.44 ± 7.75 months (p
= 0.028), ECOG 0 (49.5 ± 17.1), 1 (7.49 ± 1.38), 2 (8.78 ±
1.97) and 3 (3.88 ± 1) p = 0.003. The primary diagnosis:
lung 5.68 ± 1.25 months, breast 59.81 ± 21.12 months,
prostate 18.85 ± 5.2 months (p = 0.013). In patients with
lung cáncer, the histology was a prognostic factor:
epidermoid 2.65 ± 0.9 months, adenocarcinoma 7.69 ± 1.8
months and small cell 1.92 ± 1.32 months (p = 0.009). The
time to diagnosis of bone metastases was not prognostic
factor for survival.
Conclusion
In patients with bone metastases, the best prognosis are
breast cáncer, primary controlled, no other metastases,
SBRT and ECOG 0.
EP-1393 Prognostic factors for survival in patients with
brain metastases
P.M. Samper Ots1, M. Hernandez Miguel1, E. Amaya
Escobar1, M.D. De las Peñas Cabrera1
1 Hospital Rey Juan Carlos, servicio de oncologia
Radioterapia, Mostoles - Madrid, Spain
Purpose or Objective
To analyze the prognostic factors for survival in patients
with brain metastases.
Material and Methods
Retrospective analysis of 87 patients referred for
treatment of brain metastases, median age was 62.3 ± 13
years, 56 males (64.4 %). The most common primary
tumors were: lung 56 cases (64.4%), breast 12 (13.8 %) and
colorectal 9 (10.3%). The means time diagnosis of brain
metastases was 16.3 ± 35.36 months. 63 patients were
treated with holocraneal 3DRT (72.4%), 5 holocraneal and
boost (5.7%), 6 Stereotactic fracctionated radiotherapy
(SFR) (6.8%) and 13 no treatment (14.9%). The study was
approved by the Ethics Committee for Clinical Research
(CEIC) and meets the standards of data protection. For
statistical analysis SPSS version 22.0 was used.
Results
73 patients (83.9%) died with a median survival of 7.66 ±
0.96 months after the diagnosis of brain metastases.
Survival according to the treatment was: holocraneal
6.84 ± 0.97 months, holocraneal and boost 13.06 ± 6.04
months, SFR 7.38 ± 1.5 months and without RT 6.38 ± 2.6
months (p <0.519). The median survival after end of
radiotherapy was 6.47 ± 0.98 months. The time to
diagnosis of brain metastases, the situation of the
primary, metastases in other organs, number of brain
metastases, surgery of metastases, radiosurgery were not
prognostic factors for survival. Prognostic factors for
survival were: ECOG 0 (8.99 ± 1.43 months), 1 (8.05 ± 2.26
months), 2 (2.78 ± 0.64 months) and 3 (1.24 ± 0.94 months)
p = 0.000. Not completing radiotherapy 0.24 ± 0.12 versus
7.27 ± 1.07 months (p = 0.000). The primary diagnosis:
lung 6.96 ± 1.34 months, breast 5.38 ± 1.47 months,
colorectal 5.72 ± 2.19 months (p = 0.016). The histology:
adenocarcinoma 7.93 ± 1.99 months, infiltrating ductal
5.36 ± 1.47 months, small cell 4.94 ± 1.07 months, and
epidermoid 3.08 ± 1.0 months, (p = 0.004). In patients with
breast cancer estrogen and progesterona receptors,
negative 1.54 ± 1.3 months and positive 9.8 ± 1.03 months
(p=0.025).
Conclusion
In patients with brain metastases, the best prognosis are
lung cancer, adenocarcinoma, ECOG 0, and in breast
cancer are positive estrogen and progesterona receptors.
EP-1394 Prognostic factor for palliative radiotherapy of
bone metastases in good performance-status patients
Y. Hamamoto1, S. Taguchi2, T. Manabe2, H. Kanzaki1, K.
Nagasaki1, N. Takata1, T. Mochizuki1
1Ehime University, Radiology, Toon-city, Japan
2Saiseikai Imabari Hospital, Radiology, Imabari-city,
Japan
Purpose or Objective
Performance status is well-known prognostic factor for
patients received palliative care. Regarding patients with
good performance status, prognostic factors after
palliative intent radiation therapy (PIRT) were
investigated.
Material and Methods
Between Dec. 2009 and Mar. 2014, 148 patients received
initial PIRT in our institution. Of these, 100 patients were
able to be followed up until death or for more than six
months. Among these 100 patients, 63 patients (age, 58-
89, median 69; male/female=45/18) were in good
performance status (PS 0-1), and were reviewed in this
study. Survival time was calculated from the initiation of
initial PIRT. Assessed factors were age (<75 vs. >75), sex,
primary sites (breast vs. other organs), sites of initial PIRT
(bone/soft-tissue/lymph-nodes vs. other organs), and
administration of chemotherapy before PIRT (yes vs. no).
Univariate analysis was performed by log-rank test and
multivariate analysis was performed by Cox proportional
hazard model.
Results
Regarding all 63 patients, median survival time was seven
months and the 1-year overall survival rate was 34%. On
univariate analysis, irradiate sites was the only
statistically significant factor for survival after PIRT
(p=0.0159). Irradiate sites was the statistically significant
factor also on multivariate analysis (p=0.0179). The 1-year
overall survival rate of the patients who received PIRT to